Heron Therapeutics, Inc.HRTXNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
18.27%
↑ 3480% above average
Average (39q)
0.51%
Historical baseline
Range
High:69.56%
Low:-57.92%
CAGR
+0.6%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 18.27% |
| Q2 2025 | 28.74% |
| Q1 2025 | -28.29% |
| Q4 2024 | -28.82% |
| Q3 2024 | 0.74% |
| Q2 2024 | -3.82% |
| Q1 2024 | -57.92% |
| Q4 2023 | -19.24% |
| Q3 2023 | 2.63% |
| Q2 2023 | 49.50% |
| Q1 2023 | -20.09% |
| Q4 2022 | -56.72% |
| Q3 2022 | -11.41% |
| Q2 2022 | -31.46% |
| Q1 2022 | 45.69% |
| Q4 2021 | 0.99% |
| Q3 2021 | -18.84% |
| Q2 2021 | -7.56% |
| Q1 2021 | -14.26% |
| Q4 2020 | -9.62% |
| Q3 2020 | 11.77% |
| Q2 2020 | 19.27% |
| Q1 2020 | -23.58% |
| Q4 2019 | 39.09% |
| Q3 2019 | -16.21% |
| Q2 2019 | -3.60% |
| Q1 2019 | 7.72% |
| Q4 2018 | 31.13% |
| Q3 2018 | 0.87% |
| Q2 2018 | -23.77% |
| Q1 2018 | -17.16% |
| Q4 2017 | 65.57% |
| Q3 2017 | 0.86% |
| Q2 2017 | -14.34% |
| Q1 2017 | 13.15% |
| Q4 2016 | -2.44% |
| Q3 2016 | 10.83% |
| Q2 2016 | 69.56% |
| Q1 2016 | -1.05% |
| Q4 2015 | 14.20% |